RESEARCH STARTER

Ventilator-Associated Pneumonia (VAP)

Ventilator-Associated Pneumonia (VAP) is a serious hospital-acquired infection primarily affecting patients in intensive care units (ICUs) who are on mechanical ventilation. It typically develops within 48 hours after endotracheal intubation, leading to significant complications such as increased mortality rates, which can range from 24% to 50%, and even higher when caused by multidrug-resistant bacteria. The occurrence of VAP affects approximately 10% to 20% of patients on ventilators for more than two days, and it is associated with extended ICU stays, contributing to higher healthcare costs.

Symptoms of VAP include fever, changes in white blood cell counts, and alterations in sputum characteristics. Diagnosis remains challenging, as no standard criteria have been established, and many infections can go undetected. Current diagnostic techniques often rely on clinical evaluations and imaging, but they may lack sufficient sensitivity and specificity. Preventive strategies are essential to enhance patient outcomes, and the overuse of antibiotics is being addressed to limit the emergence of drug-resistant strains, which complicates treatment options. Understanding VAP is crucial for healthcare providers to improve management and reduce its impact on patient health and hospital resources.

Full Article

Ventilator-associated pneumonia (VAP) is a hospital-acquired (nosocomial) infection that occurs in patients receiving mechanical ventilation. Previous studies have shown that VAP affects 5 to 40 percent of patients who receive invasive mechanical ventilation for more than forty-eight hours, and it is among the most common life-threatening nosocomial infections in intensive care units (ICUs). The mortality rate associated with VAP ranges from 20 percent to 50 percent, and may be higher when multidrug-resistant pathogens are involved. Furthermore, patients with VAP have a two-fold increased risk of death compared with patients who do not develop this particular infectious disease. VAP has also been associated with a longer stay in the intensive care unit, which in turn results in an increase in hospital expenses. Preventative measures against VAP are therefore necessary to improve healthcare outcomes and to enhance the efficiency of hospital operations.

Background

VAP refers to pneumonia that develops forty-eight hours or more after endotracheal intubation, which is a procedure that involves the insertion of a tube through the nose or mouth and its attachment to a ventilator in order to facilitate breathing in a patient. VAP is characterized by the production of infiltrates or fluid within the sacs of the lungs, thus decreasing the efficiency of breathing. Other symptoms of this nosocomial infection include fever, changes in the number of white blood cells, changes in the features of the patient’s sputum, as well as detection of the actual causative agent.

VAP is one of the most common nosocomial infections in mechanically ventilated patients. It has been estimated that VAP occurs in about 5 to 40 percent of patients receiving invasive mechanical ventilation through endotracheal tubes. Furthermore, the risk of VAP is highest during the early phase of hospitalization, particularly on the first five days of attachment of a mechanical ventilator. The average time between the insertion of the endotracheal tube and the occurrence of VAP has been determined to be three days. The risk of developing VAP declines by 2 percent each day at five to ten days after ventilation and then 1 percent per day at more than ten days after.

Previous studies have indicated that the mortality rate caused by VAP ranges from 24 percent to 50 percent, and this wide range is mainly attributable to the differences in the diseases of patients in the intensive care unit. These discrepancies in mortality rates may also be due to variations in medical devices and equipment used in hospitals.

Based on the growing number of reports of VAP in intensive care units, healthcare institutions have reassessed and modified their guidelines for maintaining aseptic or bacteria-free conditions in the hospital. The implementation of improved strategies for the prevention of VAP has thus resulted in a significant decrease in the mortality rate caused by VAP, namely 9 percent to 13 percent. Furthermore, the excessive use of antibiotics has also been avoided in order to decrease the risk of developing multidrug-resistant bacterial strains in intensive care units. VAP accounts for a substantial share of antibiotic use in intensive care units. The development of multidrug-resistant bacterial strains not only increases the healthcare costs of patients but also decreases the likelihood of recovery and release from the intensive care unit. Patients who develop VAP are also at higher risk for adverse side effects that may be caused by the antibiotics they receive. Epidemiological studies on VAP have also been conducted to identify factors that increase the risk for this nosocomial infection, including male sex and trauma.

Impact

To date, no standard criteria have been established for the diagnosis of VAP. Although various clinical techniques have been developed for VAP diagnostics, these do not show significant sensitivity or specificity in accurately identifying this hospital-acquired infection. Based on these findings, most healthcare institutions have chosen to utilize daily bedside assessment, coupled with chest X-rays, in order to detect any signs of VAP in a patient. Although these approaches are not capable of precisely defining VAP, they still allow the clinician to detect any changes in the patient, particularly those involving the respiratory system.

 Studies have shown that some VAP infections in hospitals go undetected. Furthermore, VAP infections are only established when the patient dies, and an autopsy is performed. Some hospitals would utilize the inter-observer approach in evaluating a patient, wherein at least two clinicians would review the condition of a patient who has been provided with a mechanical ventilator. When the clinicians generate assessments that are clearly in agreement, the appropriate treatment is administered to the infected patient. However, when the clinicians have different assessments on whether the patient is indeed infected with VAP, then a third clinician should join in the case review. There may also be a need to include other clinical specialists who may provide insights into their VAP diagnostic scheme. It has been determined that clinical scoring approaches such as the Clinical Pulmonary Infection Score have only moderate diagnostic accuracy, with a pooled sensitivity of about 65 percent and specificity of about 64 percent.

Another VAP diagnostic approach recommended by the American Thoracic Society and the Infectious Diseases Society of America involves noninvasive lower respiratory tract sampling with semiquantitative cultures. The analysis of these specimens is then either quantitatively or qualitatively assessed. The specimens are scored in terms of VAP infection, which includes clinical, physiological, radiological, and microbiological criteria that would indicate the presence of a VAP pathogen. This approach also makes use of the correlations between the clinical features of the patient, together with other physiological parameters, and the presence of the bacterial pathogen.

Despite the applicability of this scoring system for VAP diagnostics, several clinicians have questioned the reliability and accuracy of this approach. In fact, a meta-analysis of clinical studies found that the sensitivity of this VAP scoring system was about 65 percent, and the specificity was about 64 percent. This value has prompted clinicians and researchers to scrutinize the reliability of the scoring system, including discrepancies that may emerge during inter-observer assessment. Other clinicians have identified critical physiological parameters that need to be given more consideration during VAP diagnostics, including the type of antibiotic that was administered and any cessation of antibiotic treatment over the course of a stay in the intensive care unit.

Another issue in the diagnosis and treatment of VAP is that, due to the unreliability of diagnosis, many doctors treat the disease with broad-spectrum antimicrobials in order to cover multiple possible kinds of infection, resulting in strains of pneumonia that are resistant to many drugs. A 2017 study on VAP recommended that physicians should perform bacteriological examinations of patient respiratory secretions in order to allow for more targeted antimicrobial use.


Bibliography

Almomani, Basima A., et al. “Incidence and Predictors of 14-Day Mortality in Multidrug-Resistant Acinetobacter Baumannii in Ventilator-Associated Pneumonia.” Journal of Infection in Developing Countries, vol. 9, no. 12, 30 Dec. 2015, pp. 1323–30, doi:10.3855/jidc.6812. Accessed 12 Mar. 2026.

Albin, Owen R., and Andrew J. Admon. “Accurately Measuring Preventable Ventilator-Associated Pneumonia Deaths Using Observational Data: It’s about Time.” Annals of the American Thoracic Society vol. 18, no. 5, 2021, pp. 777–79, doi:10.1513/AnnalsATS.202102-126ED. Accessed 12 Mar. 2026.

“ATS/IDSA 2016 Clinical Practice Guidelines for the Management of Adults with Hospital-Acquired and Ventilator-Associated Pneumonia.” Infectious Diseases Society of America, 14 July 2016, www.idsociety.org/practice-guideline/hap_vap/. Accessed 11 Mar. 2026.

Azab, Seham F. A., et al. “Reducing Ventilator-Associated Pneumonia in Neonatal Intensive Care Unit Using ‘VAP Prevention Bundle’: A Cohort Study.” BMC Infectious Diseases, vol. 15, no. 314, 6 Aug. 2015, pp. 1–7, doi:10.1186/s12879-015-1062-1. Accessed 12 Mar. 2026.

Bor, Canan, et al. “Ventilator-Associated Pneumonia in Critically Ill Patients with Intensive Antibiotic Usage.” Pakistan Journal of Medical Sciences, vol. 31, no. 6, 2015, pp. 1441–6, doi:10.12669/pjms.316.8038. Accessed 12 Mar. 2026.

Elliott, Doug, et al. “Incidence of Ventilator-Associated Pneumonia in Australasian Intensive Care Units: Use of a Consensus-Developed Clinical Surveillance Checklist in a Multisite Prospective Audit.” BMJ Open, vol. 5, no. 10, 29 Oct. 2015, p. e008924, doi:10.1136/bmjopen-2015-008924. Accessed 12 Mar. 2026.

Hatachi, Takeshi, et al. “Incidences and Influences of Device-Associated Healthcare-Associated Infections in a Pediatric Intensive Care Unit in Japan: A Retrospective Surveillance Study.” Journal of Intensive Care, vol. 3, no. 44, 26 Oct. 2015, doi:10.1186/s40560-015-0111-6. Accessed 12 Mar. 2026.

Li, Jiaying, et al. “Prediction Models for the Risk of Ventilator-Associated Pneumonia in Patients on Mechanical Ventilation: A Systematic Review and Meta-Analysis.” American Journal of Infection Control, vol. 52, no. 12, 2024, pp.1438–51. doi:10.1016/j.ajic.2024.07.006. Accessed 11 Mar. 2026.

Mangram, Alicia J., et al. “Trauma-Associated Pneumonia: Time to Redefine Ventilator-Associated Pneumonia in Trauma Patients.” American Journal of Surgery, vol. 210, no. 6, 2015, pp. 1056–62, doi:10.1016/j.amjsurg.2015.06.029. Accessed 12 Mar. 2026.

Philippart, François, et al. “Decreased Risk of Ventilator-Associated Pneumonia in Sepsis Due to Intra-Abdominal Infection.” PLOS ONE, vol. 10, no. 9, 4 Sept. 2015, p. e0137262. doi:10.1371/journal.pone.0137262. Accessed 12 Mar. 2026.

“Pneumonia (Ventilator-Associated [VAP] and Non-Ventilator-Associated Pneumonia [PNEU]) Event.” National Healthcare Safety Network, Jan. 2026, www.cdc.gov/nhsn/pdfs/pscmanual/6pscvapcurrent.pdf. Accessed 11 Mar. 2026.

Schnabel, Ruud, et al. “Analysis of Volatile Organic Compounds in Exhaled Breath to Diagnose Ventilator-Associated Pneumonia.” Scientific Reports, vol. 5, 26 Nov. 2015, p. 17179, doi:10.1038/srep17179. Accessed 12 Mar. 2026.

Shan, Jun, et al. “Diagnostic Accuracy of Clinical Pulmonary Infection Score for Ventilator-Associated Pneumonia: A Meta-Analysis.” Respiratory Care, vol. 56, no. 8, 2011, pp. 1087–94, doi:10.4187/respcare.01097. Accessed 11 Mar. 2026.

Timsit, Jean-Francois, et al. “Update on Ventilator-Associated Pneumonia.” F1000Research, vol. 6, 29 Nov. 2017, p. 2061, doi:10.12688/f1000research.12222.1. Accessed 12 Mar. 2026.

“Ventilator-Associated Pneumonia Basics.” Centers for Disease Control and Prevention, 22 Jan. 2024, www.cdc.gov/ventilator-associated-pneumonia/about/index.html. Accessed 11 Mar. 2026.

Zuckerman, Lisa M. “Oral Chlorhexidine Use to Prevent Ventilator-Associated Pneumonia in Adults.” Dimensions of Critical Care Nursing, vol. 35, no. 1, 2016, pp. 25–36, doi:10.1097/DCC.0000000000000154. Accessed 12 Mar. 2026.

Full Article

Ventilator-associated pneumonia (VAP) is a hospital-acquired (nosocomial) infection that occurs in patients receiving mechanical ventilation. Previous studies have shown that VAP affects 5 to 40 percent of patients who receive invasive mechanical ventilation for more than forty-eight hours, and it is among the most common life-threatening nosocomial infections in intensive care units (ICUs). The mortality rate associated with VAP ranges from 20 percent to 50 percent, and may be higher when multidrug-resistant pathogens are involved. Furthermore, patients with VAP have a two-fold increased risk of death compared with patients who do not develop this particular infectious disease. VAP has also been associated with a longer stay in the intensive care unit, which in turn results in an increase in hospital expenses. Preventative measures against VAP are therefore necessary to improve healthcare outcomes and to enhance the efficiency of hospital operations.

Background

VAP refers to pneumonia that develops forty-eight hours or more after endotracheal intubation, which is a procedure that involves the insertion of a tube through the nose or mouth and its attachment to a ventilator in order to facilitate breathing in a patient. VAP is characterized by the production of infiltrates or fluid within the sacs of the lungs, thus decreasing the efficiency of breathing. Other symptoms of this nosocomial infection include fever, changes in the number of white blood cells, changes in the features of the patient’s sputum, as well as detection of the actual causative agent.

VAP is one of the most common nosocomial infections in mechanically ventilated patients. It has been estimated that VAP occurs in about 5 to 40 percent of patients receiving invasive mechanical ventilation through endotracheal tubes. Furthermore, the risk of VAP is highest during the early phase of hospitalization, particularly on the first five days of attachment of a mechanical ventilator. The average time between the insertion of the endotracheal tube and the occurrence of VAP has been determined to be three days. The risk of developing VAP declines by 2 percent each day at five to ten days after ventilation and then 1 percent per day at more than ten days after.

Previous studies have indicated that the mortality rate caused by VAP ranges from 24 percent to 50 percent, and this wide range is mainly attributable to the differences in the diseases of patients in the intensive care unit. These discrepancies in mortality rates may also be due to variations in medical devices and equipment used in hospitals.

Based on the growing number of reports of VAP in intensive care units, healthcare institutions have reassessed and modified their guidelines for maintaining aseptic or bacteria-free conditions in the hospital. The implementation of improved strategies for the prevention of VAP has thus resulted in a significant decrease in the mortality rate caused by VAP, namely 9 percent to 13 percent. Furthermore, the excessive use of antibiotics has also been avoided in order to decrease the risk of developing multidrug-resistant bacterial strains in intensive care units. VAP accounts for a substantial share of antibiotic use in intensive care units. The development of multidrug-resistant bacterial strains not only increases the healthcare costs of patients but also decreases the likelihood of recovery and release from the intensive care unit. Patients who develop VAP are also at higher risk for adverse side effects that may be caused by the antibiotics they receive. Epidemiological studies on VAP have also been conducted to identify factors that increase the risk for this nosocomial infection, including male sex and trauma.

Impact

To date, no standard criteria have been established for the diagnosis of VAP. Although various clinical techniques have been developed for VAP diagnostics, these do not show significant sensitivity or specificity in accurately identifying this hospital-acquired infection. Based on these findings, most healthcare institutions have chosen to utilize daily bedside assessment, coupled with chest X-rays, in order to detect any signs of VAP in a patient. Although these approaches are not capable of precisely defining VAP, they still allow the clinician to detect any changes in the patient, particularly those involving the respiratory system.

 Studies have shown that some VAP infections in hospitals go undetected. Furthermore, VAP infections are only established when the patient dies, and an autopsy is performed. Some hospitals would utilize the inter-observer approach in evaluating a patient, wherein at least two clinicians would review the condition of a patient who has been provided with a mechanical ventilator. When the clinicians generate assessments that are clearly in agreement, the appropriate treatment is administered to the infected patient. However, when the clinicians have different assessments on whether the patient is indeed infected with VAP, then a third clinician should join in the case review. There may also be a need to include other clinical specialists who may provide insights into their VAP diagnostic scheme. It has been determined that clinical scoring approaches such as the Clinical Pulmonary Infection Score have only moderate diagnostic accuracy, with a pooled sensitivity of about 65 percent and specificity of about 64 percent.

Another VAP diagnostic approach recommended by the American Thoracic Society and the Infectious Diseases Society of America involves noninvasive lower respiratory tract sampling with semiquantitative cultures. The analysis of these specimens is then either quantitatively or qualitatively assessed. The specimens are scored in terms of VAP infection, which includes clinical, physiological, radiological, and microbiological criteria that would indicate the presence of a VAP pathogen. This approach also makes use of the correlations between the clinical features of the patient, together with other physiological parameters, and the presence of the bacterial pathogen.

Despite the applicability of this scoring system for VAP diagnostics, several clinicians have questioned the reliability and accuracy of this approach. In fact, a meta-analysis of clinical studies found that the sensitivity of this VAP scoring system was about 65 percent, and the specificity was about 64 percent. This value has prompted clinicians and researchers to scrutinize the reliability of the scoring system, including discrepancies that may emerge during inter-observer assessment. Other clinicians have identified critical physiological parameters that need to be given more consideration during VAP diagnostics, including the type of antibiotic that was administered and any cessation of antibiotic treatment over the course of a stay in the intensive care unit.

Another issue in the diagnosis and treatment of VAP is that, due to the unreliability of diagnosis, many doctors treat the disease with broad-spectrum antimicrobials in order to cover multiple possible kinds of infection, resulting in strains of pneumonia that are resistant to many drugs. A 2017 study on VAP recommended that physicians should perform bacteriological examinations of patient respiratory secretions in order to allow for more targeted antimicrobial use.


Bibliography

Almomani, Basima A., et al. “Incidence and Predictors of 14-Day Mortality in Multidrug-Resistant Acinetobacter Baumannii in Ventilator-Associated Pneumonia.” Journal of Infection in Developing Countries, vol. 9, no. 12, 30 Dec. 2015, pp. 1323–30, doi:10.3855/jidc.6812. Accessed 12 Mar. 2026.

Albin, Owen R., and Andrew J. Admon. “Accurately Measuring Preventable Ventilator-Associated Pneumonia Deaths Using Observational Data: It’s about Time.” Annals of the American Thoracic Society vol. 18, no. 5, 2021, pp. 777–79, doi:10.1513/AnnalsATS.202102-126ED. Accessed 12 Mar. 2026.

“ATS/IDSA 2016 Clinical Practice Guidelines for the Management of Adults with Hospital-Acquired and Ventilator-Associated Pneumonia.” Infectious Diseases Society of America, 14 July 2016, www.idsociety.org/practice-guideline/hap_vap/. Accessed 11 Mar. 2026.

Azab, Seham F. A., et al. “Reducing Ventilator-Associated Pneumonia in Neonatal Intensive Care Unit Using ‘VAP Prevention Bundle’: A Cohort Study.” BMC Infectious Diseases, vol. 15, no. 314, 6 Aug. 2015, pp. 1–7, doi:10.1186/s12879-015-1062-1. Accessed 12 Mar. 2026.

Bor, Canan, et al. “Ventilator-Associated Pneumonia in Critically Ill Patients with Intensive Antibiotic Usage.” Pakistan Journal of Medical Sciences, vol. 31, no. 6, 2015, pp. 1441–6, doi:10.12669/pjms.316.8038. Accessed 12 Mar. 2026.

Elliott, Doug, et al. “Incidence of Ventilator-Associated Pneumonia in Australasian Intensive Care Units: Use of a Consensus-Developed Clinical Surveillance Checklist in a Multisite Prospective Audit.” BMJ Open, vol. 5, no. 10, 29 Oct. 2015, p. e008924, doi:10.1136/bmjopen-2015-008924. Accessed 12 Mar. 2026.

Hatachi, Takeshi, et al. “Incidences and Influences of Device-Associated Healthcare-Associated Infections in a Pediatric Intensive Care Unit in Japan: A Retrospective Surveillance Study.” Journal of Intensive Care, vol. 3, no. 44, 26 Oct. 2015, doi:10.1186/s40560-015-0111-6. Accessed 12 Mar. 2026.

Li, Jiaying, et al. “Prediction Models for the Risk of Ventilator-Associated Pneumonia in Patients on Mechanical Ventilation: A Systematic Review and Meta-Analysis.” American Journal of Infection Control, vol. 52, no. 12, 2024, pp.1438–51. doi:10.1016/j.ajic.2024.07.006. Accessed 11 Mar. 2026.

Mangram, Alicia J., et al. “Trauma-Associated Pneumonia: Time to Redefine Ventilator-Associated Pneumonia in Trauma Patients.” American Journal of Surgery, vol. 210, no. 6, 2015, pp. 1056–62, doi:10.1016/j.amjsurg.2015.06.029. Accessed 12 Mar. 2026.

Philippart, François, et al. “Decreased Risk of Ventilator-Associated Pneumonia in Sepsis Due to Intra-Abdominal Infection.” PLOS ONE, vol. 10, no. 9, 4 Sept. 2015, p. e0137262. doi:10.1371/journal.pone.0137262. Accessed 12 Mar. 2026.

“Pneumonia (Ventilator-Associated [VAP] and Non-Ventilator-Associated Pneumonia [PNEU]) Event.” National Healthcare Safety Network, Jan. 2026, www.cdc.gov/nhsn/pdfs/pscmanual/6pscvapcurrent.pdf. Accessed 11 Mar. 2026.

Schnabel, Ruud, et al. “Analysis of Volatile Organic Compounds in Exhaled Breath to Diagnose Ventilator-Associated Pneumonia.” Scientific Reports, vol. 5, 26 Nov. 2015, p. 17179, doi:10.1038/srep17179. Accessed 12 Mar. 2026.

Shan, Jun, et al. “Diagnostic Accuracy of Clinical Pulmonary Infection Score for Ventilator-Associated Pneumonia: A Meta-Analysis.” Respiratory Care, vol. 56, no. 8, 2011, pp. 1087–94, doi:10.4187/respcare.01097. Accessed 11 Mar. 2026.

Timsit, Jean-Francois, et al. “Update on Ventilator-Associated Pneumonia.” F1000Research, vol. 6, 29 Nov. 2017, p. 2061, doi:10.12688/f1000research.12222.1. Accessed 12 Mar. 2026.

“Ventilator-Associated Pneumonia Basics.” Centers for Disease Control and Prevention, 22 Jan. 2024, www.cdc.gov/ventilator-associated-pneumonia/about/index.html. Accessed 11 Mar. 2026.

Zuckerman, Lisa M. “Oral Chlorhexidine Use to Prevent Ventilator-Associated Pneumonia in Adults.” Dimensions of Critical Care Nursing, vol. 35, no. 1, 2016, pp. 25–36, doi:10.1097/DCC.0000000000000154. Accessed 12 Mar. 2026.

More Like ThisRelated Articles

Related Articles (5)

Related Articles (5)